Statement of Changes in Beneficial Ownership (4)
January 06 2020 - 1:34PM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Wijngaard Peter |
2. Issuer Name and Ticker or Trading Symbol
MEDICINES CO /DE
[
MDCO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Development Officer |
|
(Last)
(First)
(Middle)
C/O THE MEDICINES COMPANY, 8 SYLVAN WAY |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/6/2020 |
|
(Street)
PARSIPPANY, NJ 07054
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 1/6/2020 | | D | | 107546 | D | (1) | 0 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option | $15.94 | 1/6/2020 | | D | | | 10000 | (2) | (2) | Common Stock | 10000 | $0 | 0 | D | |
| Stock Option | $22.04 | 1/6/2020 | | D | | | 17500 | (2) | (2) | Common Stock | 17500 | $0 | 0 | D | |
| Stock Option | $31.49 | 1/6/2020 | | D | | | 40995 | (2) | (2) | Common Stock | 40995 | $0 | 0 | D | |
| Stock Option | $30.55 | 1/6/2020 | | D | | | 23639 | (2) | (2) | Common Stock | 23639 | $0 | 0 | D | |
| Stock Option | $28.77 | 1/6/2020 | | D | | | 7143 | (2) | (2) | Common Stock | 7143 | $0 | 0 | D | |
| Stock Option | $28.77 | 1/6/2020 | | D | | | 30000 | (2) | (2) | Common Stock | 30000 | $0 | 0 | D | |
| Stock Option | $33.04 | 1/6/2020 | | D | | | 42539 | (2) | (2) | Common Stock | 42539 | $0 | 0 | D | |
| Stock Option | $29.01 | 1/6/2020 | | D | | | 30000 | (2) | (2) | Common Stock | 30000 | $0 | 0 | D | |
| Explanation of Responses: |
| (1) | Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"), without interest thereon and subject to any tax withholding. |
| (2) | Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option, less any required withholding taxes. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Wijngaard Peter
C/O THE MEDICINES COMPANY
8 SYLVAN WAY
PARSIPPANY, NJ 07054 |
|
| Chief Development Officer |
|
Signatures
|
| /s/ Stephen M. Rodin, Attorney-in-Fact for Peter Wijngaard | | 1/6/2020 |
| **Signature of Reporting Person | Date |
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Apr 2023 to Apr 2024
